Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Coya Therapeutics, Inc. - Common Stock
(NQ:
COYA
)
4.615
-0.025 (-0.54%)
Streaming Delayed Price
Updated: 12:56 PM EDT, Sep 15, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Coya Therapeutics, Inc. - Common Stock
< Previous
1
2
3
Next >
Get insights into the top gainers and losers of Friday's pre-market session.
↗
October 24, 2025
The US market is yet to commence its session on Friday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
Via
Chartmill
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
October 24, 2025
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
↗
October 23, 2025
Via
Benzinga
EXCLUSIVE: Coya Therapeutics Investigational Combination Therapy With GLP-1 Shows Potential For Alzheimer's Disease
↗
September 16, 2025
Coya's COYA 303 showed strong immune modulation and reduced inflammation in the brain, supporting its development for neurodegenerative diseases like Alzheimer's.
Via
Benzinga
COYA Stock Earnings: Coya Therapeutics Reported Results for Q4 2023
↗
March 19, 2024
Coya Therapeutics just reported results for the fourth quarter of 2023.
Via
InvestorPlace
Coya Therapeutics
↗
February 29, 2024
100% technical buy signals. 15 new highs and up 43.21% in the last month. 74.87+ Weighted Alpha
Via
Talk Markets
12 Health Care Stocks Moving In Monday's After-Market Session
↗
August 25, 2025
Via
Benzinga
What's Going On With Coya Therapeutics Stock?
↗
August 25, 2025
Shares of Coya Therapeutics are trading higher Monday morning. The company provided an update regarding the development of a new treatment for Amyotrophic Lateral Sclerosis.
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
August 25, 2025
Via
Benzinga
Why Meta Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket
↗
May 01, 2025
Via
Benzinga
Analyst Expectations for Coya Therapeutics's Future
↗
July 17, 2023
Via
Benzinga
The Latest Analyst Ratings for Coya Therapeutics
↗
June 08, 2023
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
↗
April 03, 2025
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
↗
March 14, 2025
Via
Benzinga
Coya Therapeutics' Alzheimer's Candidate Shows Improved Inflammatory Blood Markers Following Monthly Dosing
↗
February 06, 2025
Coya Therapeutics' Phase 2 study shows monthly LD IL-2 improves cognitive scores and reduces inflammation in Alzheimer's patients, with no serious adverse events.
Via
Benzinga
EXCLUSIVE: Coya Therapeutics Expands Its Pipeline With Combo Therapy For Inflammatory Diseases
↗
January 21, 2025
Coya Therapeutics advances COYA 303 for inflammatory diseases, combining COYA 301 and GLP-1 RA for a synergistic anti-inflammatory effect.
Via
Benzinga
Coya Therapeutics' High-Dose Interleukin-2 Misses The Mark In Mid-Stage Alzheimer's Study
↗
October 29, 2024
Coya Therapeutics reports mixed data from Phase 2 study of low-dose IL-2 in Alzheimer's, showing safety and potential cognitive benefits in q4wks regimen.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
↗
October 29, 2024
Via
Benzinga
This Yelp Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday
↗
September 16, 2024
Via
Benzinga
COYA Stock Earnings: Coya Therapeutics Misses EPS, Misses Revenue for Q2 2024
↗
August 12, 2024
COYA stock results show that Coya Therapeutics missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
Via
InvestorPlace
7 Biotech Stocks to Put on Your Breakthrough Radar
↗
May 27, 2024
Although biotech stocks can present volatility risks due to its feast-or-famine nature, their narrative offers permanent relevance.
Via
InvestorPlace
EXCLUSIVE: Coya Therapeutics, Focused On Neurodegenerative Diseases Has Gained 70% Since IPO; CEO Highlights Efforts On Combination Therapy For Rare Diseases
↗
May 27, 2024
Coya Therapeutics is working On neurodegenerative disease treatment with its combination therapies targeting regulatory T cells. CEO Howard Berman discusses the potential of COYA 302 for ALS, FTD,...
Via
Benzinga
COYA Stock Earnings: Coya Therapeutics Misses EPS for Q1 2024
↗
May 09, 2024
COYA stock results show that Coya Therapeutics missed analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
Coya Therapeutics Secures Key Financing In Its Fight Against Myriad Diseases
↗
February 05, 2024
Dr. Howard Burman, Ph.D, CEO and Dr. Arun Swaminathan, CBO, of Coya Therapeutics Inc (NASDAQ: COYA), were guests on Benzinga’s All Access.
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
↗
December 01, 2023
Via
Benzinga
How The Same Treatments May Work For Multiple Neurodegenerative Diseases
↗
September 21, 2023
Extensive research on NDDs has uncovered a different treatment pathway that's enabling some biotechnology firms to target more than one NDD with the same drug candidate.
Via
Talk Markets
12 Health Care Stocks Moving In Thursday's Intraday Session
↗
September 07, 2023
Via
Benzinga
Coya Therapeutics' Alzheimer's Candidate Shows Lower Biomarker Levels Associated With Neuroinflammation
↗
July 17, 2023
Coya Therapeutics Inc (NASDAQ: COYA) reported results from an open-label proof-of-concept clinical study for low-dose interleukin 2 (ld IL-2) in patients
Via
Benzinga
The Immunotherapy Market Is Expected To Surpass $351.56 Billion By 2030 – Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) Is Contributing to This Growth
↗
July 12, 2023
Immunotherapy, in general, is an exciting and growing sector in the pharmaceutical industry. It involves manipulating the human body's immune system to treat various diseases. While historically this...
Via
Benzinga
Marsh & McLennan To Rally Around 14%? Here Are 10 Other Analyst Forecasts For Thursday
↗
June 08, 2023
Raymond James cut the price target for Brinker International, Inc. (NYSE: EAT) from $46 to $42.5. Raymond James analyst Brian Vaccaro maintained an Outperform rating. Brinker shares fell 6.3% to close...
Via
Benzinga
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
